Optimization of levofloxacin-loaded crosslinked chitosan microspheres for inhaled aerosol therapy

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 96, Issue , 2015, Pages 65-75

  Gaspar, Marisa C ^a,b   Sousa, João J S ^a,b   Pais, Alberto A C C ^c   Cardoso, Olga ^b   Murtinho, Dina ^c   Serra, M Elisa S ^c   Tewes, Frédéric ^d,e   Olivier, Jean Christophe ^d,e  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d INSERM   (France)

^e UNIVERSITÉ DE POITIERS   (France)

Author keywords

Aerosol; Chitosan; Crosslinking agents; Cystic Fibrosis; Experimental design; Levofloxacin; Lung delivery; Microspheres

Indexed keywords

CHITOSAN; GENIPIN; GLUTARALDEHYDE; GLUTARIC ACID; GLYCERALDEHYDE; LEVOFLOXACIN; MICROSPHERE; ANTIINFECTIVE AGENT; CROSS LINKING REAGENT; DRUG CARRIER;

AEROSOL; AIRFLOW; ANTIBACTERIAL ACTIVITY; ARTICLE; CROSS LINKING; CYSTIC FIBROSIS; DRUG RELEASE; DRY POWDER INHALER; FACTORIAL DESIGN; HIGH TEMPERATURE; IN VITRO STUDY; INHALATIONAL DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; PARTICLE SIZE; PROCESS OPTIMIZATION; PSEUDOMONAS INFECTION; SPRAY DRYING; CHEMISTRY; DRUG EFFECTS; HUMAN; INFRARED SPECTROSCOPY; ISOLATION AND PURIFICATION; MICROBIOLOGY; PHARMACEUTICS; POWDER DIFFRACTION; PROCEDURES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY CARE; SURFACE PROPERTY;

ANTI-BACTERIAL AGENTS; CHITOSAN; CROSS-LINKING REAGENTS; CYSTIC FIBROSIS; DRUG CARRIERS; DRUG LIBERATION; HUMANS; LEVOFLOXACIN; MICROSPHERES; PARTICLE SIZE; POWDER DIFFRACTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY THERAPY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL;

EID: 84937849581     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2015.07.010     Document Type: Article

References (65)

1. M.Y. Ng, W. Flight, and E. Smith Pulmonary complications of cystic fibrosis Clin. Radiol. 69 3 2014 e153 e162 10.1016/j.crad.2013.10.023
2. N. Høiby Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis BMC Med. 9 1 2011 32 38 10.1186/1741-7015-9-32
3. C. Stockmann, C.M.T. Sherwin, K. Ampofo, and M.G. Spigarelli Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis Ther. Adv. Respir. Dis. 8 1 2014 13 21 10.1177/1753465813508445
4. D.E. Geller Aerosol antibiotics in cystic fibrosis Respir. Care 54 5 2009 658 670
5. S. Kirkby, K. Novak, and K. McCoy Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review Core Evidence 6 2011 59 66
6. G.S. Sawicki, J.E. Signorovitch, J. Zhang, D. Latremouille-Viau, M. von Wartburg, E.Q. Wu, and L. Shi Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution Pediatr. Pulmonol. 47 1 2012 44 52 10.1002/ppul.21521
7. Foundation CF, Drug Development Pipeline, 2012. "http://www.cff.org/research/DrugDevelopmentPipeline/" (accessed 07.01.15).
8. X.M. Zeng, G.P. Martin, and C. Marriott The controlled delivery of drugs to the lung Int. J. Pharm. 124 2 1995 149 164 10.1016/0378-5173(95)00104-q
9. A. Saigal, W.K. Ng, R.B.H. Tan, and S.Y. Chan Development of controlled release inhalable polymeric microspheres for treatment of pulmonary hypertension Int. J. Pharm. 450 1-2 2013 114 122 10.1016/j.ijpharm.2013.04.011
10. M.C. Gaspar, W. Couet, J.C. Olivier, A.A.C.C. Pais, and J.J.S. Sousa Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review Eur. J. Clin. Microbiol. Infect. Dis. 32 10 2013 1231 1252 10.1007/s10096-013-1876-y
11. C. Loira-Pastoriza, J. Todoroff, and R. Vanbever Delivery strategies for sustained drug release in the lungs Adv. Drug Deliv. Rev. 75 2014 81 91 10.1016/j.addr.2014.05.017
12. J. Du, I. El-Sherbiny, and H. Smyth Swellable ciprofloxacin-loaded nano-in-micro hydrogel particles for local lung drug delivery AAPS PharmSciTech 15 6 2014 1535 1544 10.1208/s12249-014-0176-x
13. I.M. El-Sherbiny, S. McGill, and H.D. Smyth Swellable microparticles as carriers for sustained pulmonary drug delivery J. Pharm. Sci. 99 5 2010 2343 2356
14. M.S. Benhabiles, R. Salah, H. Lounici, N. Drouiche, M.F.A. Goosen, and N. Mameri Antibacterial activity of chitin, chitosan and its oligomers prepared from shrimp shell waste Food Hydrocolloids 29 1 2012 48 56 10.1016/j.foodhyd.2012.02.013
15. D. Raafat, K. von Bargen, A. Haas, and H.-G. Sahl Insights into the mode of action of chitosan as an antibacterial compound Appl. Environ. Microbiol. 74 12 2008 3764 3773 10.1128/aem.00453-08
16. H. Feng, L. Zhang, and C. Zhu Genipin crosslinked ethyl cellulose-chitosan complex microspheres for anti-tuberculosis delivery Colloids Surf., B 103 2013 530 537 10.1016/j.colsurfb.2012.11.007
17. A. Bigi, G. Cojazzi, S. Panzavolta, K. Rubini, and N. Roveri Mechanical and thermal properties of gelatin films at different degrees of glutaraldehyde crosslinking Biomaterials 22 8 2001 763 768 10.1016/S0142-9612(00)00236-2
18. A. Bigi, G. Cojazzi, S. Panzavolta, N. Roveri, and K. Rubini Stabilization of gelatin films by crosslinking with genipin Biomaterials 23 24 2002 4827 4832 10.1016/S0142-9612(02)00235-1
19. C.A. Ventura, S. Tommasini, E. Crupi, I. Giannone, V. Cardile, T. Musumeci, and G. Puglisi Chitosan microspheres for intrapulmonary administration of moxifloxacin: interaction with biomembrane models and in vitro permeation studies Eur. J. Pharm. Biopharm. 68 2 2008 235 244 10.1016/j.ejpb.2007.05.011
20. M. Abdel Mouez, N.M. Zaki, S. Mansour, and A.S. Geneidi Bioavailability enhancement of verapamil HCl via intranasal chitosan microspheres Eur. J. Pharm. Sci. 51 2014 59 66 10.1016/j.ejps.2013.08.029
21. M.D. Dhanaraju, S. Elizabeth, and T. Gunasekaran Triamcinolone-loaded glutaraldehyde cross-linked chitosan microspheres: prolonged release approach for the treatment of rheumatoid arthritis Drug Deliv. 18 3 2011 198 207
22. S. Ramachandran, S. Nandhakumar, and M.D. Dhanaraju Formulation and characterization of glutaraldehyde cross-linked chitosan biodegradable microspheres loaded with famotidine Trop. J. Pharm. Res. 10 3 2011 309 316 10.4314/tjpr.v10i3.13
23. F.-L. Mi, S.-S. Shyu, and C.-K. Peng Characterization of ring-opening polymerization of genipin and pH-dependent cross-linking reactions between chitosan and genipin J. Polym. Sci., Part A: Polym. Chem. 43 10 2005 1985 2000 10.1002/pola.20669
24. C. Nishi, N. Nakajima, and Y. Ikada In vitro evaluation of cytotoxicity of diepoxy compounds used for biomaterial modification J. Biomed. Mater. Res. 29 7 1995 829 834
25. H.W. Sung, R.N. Huang, L.L. Huang, and C.C. Tsai In vitro evaluation of cytotoxicity of a naturally occurring cross-linking reagent for biological tissue fixation J. Biomater. Sci. Polym. Ed. 10 1 1999 63 78
26. T. Mitra, G. Sailakshmi, and A. Gnanamani Could glutaric acid (GA) replace glutaraldehyde in the preparation of biocompatible biopolymers with high mechanical and thermal properties? J. Chem. Sci. 126 1 2014 127 140 10.1007/s12039-013-0543-2
27. G. Sailakshmi, M. Tapas, C. Suvro, and A. Gnanamani Chemistry behind the elastic nature of the biomaterial prepared using oxidized form of glutaraldehyde and chitosan - an approach at 2D and 3D level Int. J. Life Sci. Med. Res. 4 2 2013 64 75 10.5963/LSMR0302004
28. B.F. Oliveira, M.H.A. Santana, and M.I. Ré Spray-dried chitosan microspheres cross-linked with d,l-glyceraldehyde as a potential drug delivery system: preparation and characterization Braz. J. Chem. Eng. 22 2005 353 360
29. M.A. Vandelli, F. Rivasi, P. Guerra, F. Forni, and R. Arletti Gelatin microspheres crosslinked with d,l-glyceraldehyde as a potential drug delivery system: preparation, characterisation, in vitro and in vivo studies Int. J. Pharm. 215 1-2 2001 175 184 10.1016/S0378-5173(00)00681-5
30. B. Conti, T. Modena, I. Genta, P. Perugini, and F. Pavanetto A proposed new method for the crosslinking of chitosan microspheres Drug Deliv. 5 2 1998 87 93 10.3109/10717549809031383
31. P. Piyakulawat, N. Praphairaksit, N. Chantarasiri, and N. Muangsin Preparation and evaluation of chitosan/carrageenan beads for controlled release of sodium diclofenac AAPS PharmSciTech 8 4 2007
32. C. Muzzarelli, V. Stanic, L. Gobbi, G. Tosi, and R.A.A. Muzzarelli Spray-drying of solutions containing chitosan together with polyuronans and characterisation of the microspheres Carbohydr. Polym. 57 1 2004 73 82 10.1016/j.carbpol.2004.04.002
33. A. Elzoghby, W. Samy, and N. Elgindy Novel spray-dried genipin-crosslinked casein nanoparticles for prolonged release of alfuzosin hydrochloride Pharm. Res. 30 2 2013 512 522 10.1007/s11095-012-0897-z
34. J.W. Eaton, GNU Octave Software, Version 3.2.3, 2009.
35. T.V. Doan, W. Couet, and J.C. Olivier Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery Int. J. Pharm. 414 1-2 2011 112 117 10.1016/j.ijpharm.2011.05.007
36. R. Osman, P.L. Kan, G. Awad, N. Mortada, A.-E. El-Shamy, and O. Alpar Spray dried inhalable ciprofloxacin powder with improved aerosolisation and antimicrobial activity Int. J. Pharm. 449 1-2 2013 44 58 10.1016/j.ijpharm.2013.04.009
37. V. Jain, D. Prasad, D. Jain, S.K. Mishra, and R. Singh Factorial design-based development of measlamine microspheres for colonic delivery Biomatter 1 2 2011 182 188
38. F. Tewes, K.J. Paluch, L. Tajber, K. Gulati, D. Kalantri, C. Ehrhardt, and A.M. Healy Steroid/mucokinetic hybrid nanoporous microparticles for pulmonary drug delivery Eur. J. Pharm. Biopharm. 85 3, Part A 2013 604 613 10.1016/j.ejpb.2013.03.02
39. M.I. Amaro, F. Tewes, O. Gobbo, L. Tajber, O.I. Corrigan, C. Ehrhardt, and A.M. Healy Formulation, stability and pharmacokinetics of sugar-based salmon calcitonin-loaded nanoporous/nanoparticulate microparticles (NPMPs) for inhalation Int. J. Pharm. 483 1-2 2015 6 18 10.1016/j.ijpharm.2015.02.003
40. E. Matuschek, D.F. Brown, and G. Kahlmeter Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories Clin. Microbiol. Infect. 20 4 2014 O255 O266
41. CLSI, Performance Standards for Antimicrobial Susceptibility Testing Twenty-Fourth Informational Supplement, CLSI Document M100-S24, 2014.
42. W.S. Cheow, M.W. Chang, and K. Hadinoto Antibacterial efficacy of inhalable levofloxacin-loaded polymeric nanoparticles against E. coli biofilm cells: the effect of antibiotic release profile Pharm. Res. 27 8 2010 1597 1609
43. H. Adi, P.M. Young, H.-K. Chan, H. Agus, and D. Traini Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease Eur. J. Pharm. Sci. 40 3 2010 239 247 10.1016/j.ejps.2010.03.020
44. R. Vehring Pharmaceutical particle engineering via spray drying Pharm. Res. 25 5 2008 999 1022 10.1007/s11095-007-9475-1
45. J. Elversson, A. Millqvist-Fureby, G. Alderborn, and U. Elofsson Droplet and particle size relationship and shell thickness of inhalable lactose particles during spray drying J. Pharm. Sci. 92 4 2003 900 910 10.1002/jps.10352
46. S. Belotti, A. Rossi, P. Colombo, R. Bettini, D. Rekkas, S. Politis, G. Colombo, A.G. Balducci, and F. Buttini Spray dried amikacin powder for inhalation in cystic fibrosis patients: a quality by design approach for product construction Int. J. Pharm. 471 1-2 2014 507 515 10.1016/j.ijpharm.2014.05.055
47. K.S. Patel, and M.B. Patel Preparation and evaluation of chitosan microspheres containing nicorandil Int. J. Pharm. Invest. 4 1 2014 32 37
48. E.M. Gorman, B. Samas, and E.J. Munson Understanding the dehydration of levofloxacin hemihydrate J. Pharm. Sci. 101 9 2012 3319 3330 10.1002/jps.23200
49. J. Kawadkar, and M.K. Chauhan Intra-articular delivery of genipin cross-linked chitosan microspheres of flurbiprofen: preparation, characterization, in vitro and in vivo studies Eur. J. Pharm. Biopharm. 81 3 2012 563 572 10.1016/j.ejpb.2012.04.018
50. X. Zhao, K. Song, S. Wang, Y. Zu, N. Li, and X. Yu Micronization of the pharmaceutically active agent genipin by an antisolvent precipitation process Chem. Eng. Technol. 36 1 2013 33 42 10.1002/ceat.201200036
51. A.B. Dhanikula, and R. Panchagnula Development and characterization of biodegradable chitosan films for local delivery of paclitaxel AAPS J. 6 3 2004 88 99 10.1208/aapsj060327
52. W. Rojanarat, T. Nakpheng, E. Thawithong, N. Yanyium, and T. Srichana Levofloxacin-proliposomes: opportunities for use in lung tuberculosis Pharmaceutics 4 3 2012 385 412
53. V.k. Shahwal, B.K. Dubey, and M. Bhoumick Preformulation study of levofloxacin Int. J. Adv. Pharm. 1 1 2012 8
54. E. Bulut In-vitro evaluation of ibuprofen-loaded microspheres prepared from novel chitosan/poly(vinyl alcohol) interpenetrating polymer network Polym.-Plast. Technol. Eng. 53 4 2014 371 378 10.1080/03602559.2013.844250
55. V.L. Gonçalves, M.C.M. Laranjeira, V.T. Fávere, and R.C. Pedrosa Effect of crosslinking agents on chitosan microspheres in controlled release of diclofenac sodium Polímeros 15 2005 6 12
56. M.J. O'Neil The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals 2006 Merck and Co., Inc Whitehouse Station, NJ
57. D.E. Geller, P.A. Flume, D. Staab, R. Fischer, J.S. Loutit, and D.J. Conrad Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa Am. J. Respir. Crit. Care Med. 183 11 2011 1510 1516 10.1164/rccm.201008-1293OC
58. S.B. Fiel Aerosolized antibiotics in cystic fibrosis: an update Expert Rev. Respir. Med. 8 3 2014 305 314 10.1586/17476348.2014.896205
59. J. Shur, S. Lee, W. Adams, R. Lionberger, J. Tibbatts, and R. Price Effect of device design on the in vitro performance and comparability for capsule-based dry powder inhalers AAPS J. 14 4 2012 667 676 10.1208/s12248-012-9379-9
60. M.J. Donovan, S.H. Kim, V. Raman, and H.D. Smyth Dry powder inhaler device influence on carrier particle performance J. Pharm. Sci. 101 3 2012 1097 1107 10.1002/jps.22824
61. T.P. Learoyd, J.L. Burrows, E. French, and P.C. Seville Chitosan-based spray-dried respirable powders for sustained delivery of terbutaline sulfate Eur. J. Pharm. Biopharm. 68 2 2008 224 234 10.1016/j.ejpb.2007.04.017
62. I.J. Smith, and M. Parry-Billings The inhalers of the future? A review of dry powder devices on the market today Pulm. Pharmacol. Ther. 16 2 2003 79 95 10.1016/S1094-5539(02)00147-5
63. D.O. Corrigan, A.M. Healy, and O.I. Corrigan Preparation and release of salbutamol from chitosan and chitosan co-spray dried compacts and multiparticulates Eur. J. Pharm. Biopharm. 62 3 2006 295 305 10.1016/j.ejpb.2005.09.008
64. H.-J. Koo, K.-H. Lim, H.-J. Jung, and E.-H. Park Anti-inflammatory evaluation of gardenia extract, geniposide and genipin J. Ethnopharmacol. 103 3 2006 496 500 10.1016/j.jep.2005.08.011
65. M. Kong, X.G. Chen, K. Xing, and H.J. Park Antimicrobial properties of chitosan and mode of action: a state of the art review Int. J. Food Microbiol. 144 1 2010 51 63 10.1016/j.ijfoodmicro.2010.09.012